AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34765950
Drug: GM1 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM1 (60 mg daily for 3 weeks or 40 mg daily for 2 weeks)
Trial: 33543381
Drug: Subgingival debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival debridement (SD) with light-activated disinfection (LAD) plus probiotic treatment
Trial: 32921680
Drug: Dapagliflozin 5
RxNorm normalized name: dapagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 5 mg/day add-on
Trial: 32921680
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy add-on
Trial: 36153496
Drug: Atezolizumab maintenance
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab maintenance therapy with thoracic radiotherapy (TRT)
Trial: 36153496
Drug: Atezolizumab maintenance
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab maintenance therapy without thoracic radiotherapy (TRT)
Trial: 37037952
Drug: Chemotherapy (KEYNOTE-061)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (KEYNOTE-061)
Trial: 37037952
Drug: Chemotherapy (KEYNOTE-062)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (KEYNOTE-062)
Trial: 34185259
Drug: Denosumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (120 mg) subcutaneously every 3–4 weeks for about 6 months and then every 3 months for a total treatment duration of 5 years
Trial: 34185259
Drug: Denosumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (120 mg) subcutaneously
Trial: 33032163
Drug: Floatation‐restricted environmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floatation‐restricted environmental stimulation therapy (floatation‐REST)
Trial: 34159460
Drug: Senna laxative
RxNorm normalized name: Senna Laxative
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Senna laxative for 3 days followed by low volume PEG on examination day
Trial: 34159460
Drug: Senna laxative
RxNorm normalized name: Senna Laxative
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Senna laxative
Trial: 34521554
Drug: Lurbinectedin 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin 3.2 mg/m2 1-h i.v. infusion q3wk
Trial: 34521554
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 1-h i.v. infusion q4wk or topotecan 1.50 mg/m2 30-min i.v. infusion Days 1-5 q3wk
Trial: 33200180
Drug: Diet-related interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet-related interventions (diet and/or behavioral manipulation, provision of foods or entire meals, or delivery of dietary components in individual food items or supplements)
Trial: 33878954
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy plus pembrolizumab
Trial: 33878954
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy followed by pembrolizumab
Trial: 33878954
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care adjuvant platinum-based chemotherapy
Trial: 35238401
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia (target‐controlled total intravenous anaesthesia with propofol and remifentanil)
Trial: 35292486
Drug: 3-hour training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hour training for neurologists on how to provide complex information about MS escalation therapy
Trial: 32788041
Drug: Subcutaneous border
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous border plating (± hook)
Trial: 35300506
Drug: Azelastine add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine add-on therapy and Budesonide nasal spray
Trial: 35300506
Drug: Montelukast add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast add-on therapy and Budesonide nasal spray
Trial: 35300506
Drug: Intranasal Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal Budesonide spray with placebo tablet (Control)
Trial: 35738244
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of Dialectical Behavior Therapy (DBT-6)
Trial: 35738244
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of Dialectical Behavior Therapy (DBT-12)
Trial: 33823285
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine (Rova‐T) 0.3 mg/kg every 6 weeks (omitted every third cycle)
Trial: 32645213
Drug: Adjunctive perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive perampanel (maximum dose = 12 mg/d)
Trial: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at 1.2 mmol L‐1
Trial: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at 2.4 mmol L‐1
Trial: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at 3.6 mmol L‐1
Trial: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at 1.2, 2.4, and 3.6 mmol L‐1
Trial: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at all concentrations (1.2, 2.4, and 3.6 mmol L‐1)
Trial: 36419123
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) exposure at 150 µg/m3 PM2.5 for 4 hours
Trial: 36419123
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) exposure at varying concentrations (20, 50, 150 µg/m3 PM2.5)
Trial: 33880724
Drug: Accelerated Partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Partial Breast Irradiation (APBI) - 3D conformal external irradiation, 3.75 Gy/fraction, twice a day, 5 fractions/week, total dose 37.5 Gy
Trial: 33880724
Drug: Whole Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Breast Irradiation (WBI) - 3D conformal external irradiation, 2 Gy daily/fraction, 5 fractions/week, total dose 50 Gy
Trial: 33322629
Drug: Bovine milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine milk-based multicomponent fortifier and protein supplement
Trial: 33322629
Drug: Donkey milk-derived
RxNorm normalized name: Recombinant human C1-inhibitor rabbit milk derived
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Donkey milk-derived multicomponent fortifier and protein supplement
Trial: 32984909
Drug: Oral plus
RxNorm normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral plus intravenous (IV) antibiotic prophylaxis (AP) - oral erythromycin 500 mg + metronidazole 500 mg a day before surgery and 1,000 mg of cephalosporin IV 30–90 min before operation
Trial: 32984909
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) antibiotic prophylaxis only
Trial: 35644960
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with 1% tetracaine
Trial: 35277087
Drug: E5 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5 group (0.25 mg/kg i.v. loading dose of esmolol, followed by 5 µg/kg/min infusion)
Trial: 35277087
Drug: E10 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E10 group (0.5 mg/kg i.v. loading dose of esmolol, followed by 10 µg/kg/min infusion)
Trial: 34474441
Drug: Ketamine by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine by intravenous continuous infusion (0.25 mg/kg/h)
Trial: 34474441
Drug: Ketamine by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine by intravenous bolus (0.25 mg/kg every hour)
Trial: 34474441
Drug: Ketamine by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine by intravenous bolus
Trial: 34474441
Drug: Ketamine by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine by intravenous continuous infusion
Trial: 33893522
Drug: Cell therapy
RxNorm normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell therapy (mesenchymal stem cells)
Trial: 34228877
Drug: Intralesional Candida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Candida antigen (0.3 ml injection)
Trial: 34228877
Drug: Intralesional vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional vitamin D3 (0.6 ml, 60,000 IU injection)
Trial: 34228877
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.3 ml injection)
Trial: 32481563
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg red Korean ginseng extract per day for seven days
Trial: 36196711
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (HSS) infusion plus standard diuretics therapy (SDT)
Trial: 36196711
Drug: Etilefrine tablets
RxNorm normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etilefrine tablets plus standard diuretics therapy (SDT)
Trial: 36196711
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HSS infusion and etilefrine tablets plus standard diuretics therapy (SDT)
Trial: 36196711
Drug: Standard diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diuretics therapy (SDT) alone
Trial: 32654558
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker therapy
Trial: 34866258
Drug: Oral dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dextrose as first line treatment
Trial: 34866258
Drug: Re-checking blood
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-checking blood glucose concentrations after oral dextrose
Trial: 34866258
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of intravenous dextrose
Trial: 34088224
Drug: 30% oral
RxNorm normalized name: Lactobacillus Acidophilus/Lactobacillus Bifidus 70%-30% Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oral glucose solution (GG)
Trial: 32865148
Drug: PST-Hospice (Brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PST-Hospice (Brief Problem-Solving Therapy)
Trial: 36401749
Drug: Add-on Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add-on Celecoxib 400 mg/day
Trial: 33478570
Drug: Silver needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver needle therapy (SNT) and physiotherapy
Trial: 33478570
Drug: Silver needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver needle therapy (SNT)
Trial: 33070152
Drug: Fenofibrate 10
RxNorm normalized name: fenofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 10 mg/kg/day for 1 day or 2 days
Trial: 34618982
Drug: Omega-3 free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 free carboxylic acids (OM-3CA) 4 g per day
Trial: 38837237
Drug: Doxepin cream
RxNorm normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin cream
Trial: 35749440
Drug: Telehealth behaviour
RxNorm normalized name: Guaifenesin 100 mg in 5 mL ORAL LIQUID [SelectHealth Tussin DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth behaviour intervention (3 times per week for 12 weeks, including home-based exercise twice a week and individual lifestyle program once a week)
Trial: 37586845
Drug: Colchicine treatment
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine treatment
Trial: 32476162
Drug: Eflapegrastim 13.2
RxNorm normalized name: EFLAPEGRASTIM 13.2 mg in 0.6 mL SUBCUTANEOUS INJECTION, SOLUTION [Rolvedon]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflapegrastim 13.2 mg (3.6 mg G-CSF)
Trial: 32476162
Drug: Pegfilgrastim 6
RxNorm normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim 6 mg G-CSF
Trial: 33958268
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg/day for 14 weeks
Trial: 36549749
Drug: Common Elements
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common Elements Treatment Approach (CETA)
Trial: 35594631
Drug: Concentrated fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated fish oil (FO) 3 g/d
Trial: 35594631
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (CO) 3 g/d
Trial: 35229616
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy after 1 month (with aspirin for the first month)
Trial: 35229616
Drug: Standard dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dual antiplatelet therapy for 1 year followed by aspirin alone
Trial: 35229616
Drug: Standard dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dual antiplatelet therapy
Trial: 34678198
Drug: Typhoid Conjugate
RxNorm normalized name: Typhoid conjugate vaccine (TCV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhoid Conjugate Vaccine (TCV)
Trial: 34187937
Drug: Intra-articular Corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular Corticosteroid Injection (IACI) with 40mg Triamcinolone and 1ml 2% Lignocaine
Trial: 33284237
Drug: nal‐IRI 50 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nal‐IRI 50 mg/m2 every 2 weeks + TMZ 50 mg/m2/d
Trial: 33284237
Drug: nal‐IRI 70 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nal‐IRI 70 mg/m2 every 2 weeks + TMZ 50 mg/m2/d
Trial: 32085778
Drug: Open-abdomen (OA)
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-abdomen (OA) approach with active negative pressure peritoneal therapy
Trial: 34663672
Drug: Daily mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mobile phone instructional text messages to perform regular outdoor walking and functional leg exercises (n=40)
Trial: 35499216
Drug: Telitacicept (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telitacicept (80 or 160 mg per week)
Trial: 33186125
Drug: Integrated yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated yoga therapy (performed 3 to 4 times weekly at home with 1 in-office session weekly for the first month)
Trial: 33186125
Drug: Integrated yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated yoga therapy
Trial: 34496755
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 4 mg with 0.5% ropivacaine
Trial: 34496755
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 4 mg
Trial: 36159553
Drug: Qigong (QG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qigong (QG) rehabilitation therapy
Trial: 36159553
Drug: Routine cardiologic
RxNorm normalized name: Cardiology Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine cardiologic medication (Control)
Trial: 33287570
Drug: Curcuma longa
RxNorm normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma longa and Boswellia serrata extracts (two tablets twice a day for 1 month)
Trial: 35548913
Drug: tiapride, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiapride, 100 mg twice daily
Trial: 35548913
Drug: topiramate, 25
RxNorm normalized name: Topiramate, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topiramate, 25 mg twice daily
Trial: 33148343
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of evidence-based protocols for stroke management in the ED, including triage, administration of tissue plasminogen activator, management of fever, hyperglycaemia, and swallowing, and transfer to a stroke unit.
Trial: 34195864
Drug: ThrIVe-B intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThrIVe-B intervention plus treatment as usual
Trial: 32340616
Drug: Automated digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated digital reminders + personalized prescribed treatment plan (pPTP)
Trial: 37104214
Drug: Proton-Pump Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-Pump Inhibitors (PPIs)
Trial: 34112266
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care based on intensive insulin therapy
Trial: 32949255
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV butylscopolamine 100 mg/24 h
Trial: 32007230
Drug: Ticagrelor +
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor + Aspirin for 3 months, then Ticagrelor alone for 9 months
Trial: 32007230
Drug: Clopidogrel +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel + Aspirin for 3 months, then Clopidogrel alone for 9 months
Trial: 33512799
Drug: Low-dose GLP-2
RxNorm normalized name: (Gly2)GLP-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose GLP-2 (1 pmol × kg × min)
Trial: 33512799
Drug: High-dose GLP-2
RxNorm normalized name: (Gly2)GLP-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GLP-2 (10 pmol × kg × min)
Trial: 34245356
Drug: Signal Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Signal Daily White (SDW)
Trial: 32506363
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) with idarucizumab reversal in dabigatran-treated patients
Trial: 36086723
Drug: Lidocaine (2%)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (2%) 1.5 mg/kg bolus before induction followed by 2 mg/kg/h continuous infusion up to skin closure
Trial: 36326756
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg dose of ERBB2 ICD plasmid-based vaccine
Trial: 36326756
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg dose of ERBB2 ICD plasmid-based vaccine
Trial: 36326756
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg and 500 μg doses of ERBB2 ICD plasmid-based vaccine
Trial: 36326756
Drug: Highest vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest vaccine dose (500 μg)
Trial: 33616843
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera 3% ointment, 1 g twice daily for 6 weeks
Trial: 32044621
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 50 mg
Trial: 33710717
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (14 mg)
Trial: 32055016
Drug: 24 GyE
RxNorm normalized name: DIMETHICONE 0.6 g in 100 mL TOPICAL SHAMPOO [GYEOL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 GyE proton beam therapy (PBT) with intravitreal anti-VEGF therapy
Trial: 32055016
Drug: 24 GyE
RxNorm normalized name: DIMETHICONE 0.6 g in 100 mL TOPICAL SHAMPOO [GYEOL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 GyE proton beam therapy (PBT)
Trial: 35589614
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (meta-analysis)
Trial: 32475902
Drug: Repaglinide monotherapy
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide monotherapy
Trial: 35934637
Drug: Sub-epidermal moisture
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-epidermal moisture scanning (SEMS) daily